These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

495 related articles for article (PubMed ID: 11753385)

  • 1. BCR-ABL suppresses C/EBPalpha expression through inhibitory action of hnRNP E2.
    Perrotti D; Cesi V; Trotta R; Guerzoni C; Santilli G; Campbell K; Iervolino A; Condorelli F; Gambacorti-Passerini C; Caligiuri MA; Calabretta B
    Nat Genet; 2002 Jan; 30(1):48-58. PubMed ID: 11753385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High levels of the BCR/ABL oncoprotein are required for the MAPK-hnRNP-E2 dependent suppression of C/EBPalpha-driven myeloid differentiation.
    Chang JS; Santhanam R; Trotta R; Neviani P; Eiring AM; Briercheck E; Ronchetti M; Roy DC; Calabretta B; Caligiuri MA; Perrotti D
    Blood; 2007 Aug; 110(3):994-1003. PubMed ID: 17475908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effect and possible mechanism of HnRNP E2 decoy RNA on proliferation of K562 leukemia cells].
    Chen XM; Feng WL; Zhao SQ; Zeng JM; Bai WJ; Wang XZ; Huang ZG
    Ai Zheng; 2006 Jul; 25(7):793-7. PubMed ID: 16831266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disruption of the inhibitor of apoptosis protein survivin sensitizes Bcr-abl-positive cells to STI571-induced apoptosis.
    Wang Z; Sampath J; Fukuda S; Pelus LM
    Cancer Res; 2005 Sep; 65(18):8224-32. PubMed ID: 16166298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p210BCR-ABL inhibits SDF-1 chemotactic response via alteration of CXCR4 signaling and down-regulation of CXCR4 expression.
    Geay JF; Buet D; Zhang Y; Foudi A; Jarrier P; Berthebaud M; Turhan AG; Vainchenker W; Louache F
    Cancer Res; 2005 Apr; 65(7):2676-83. PubMed ID: 15805265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TLS/FUS, a pro-oncogene involved in multiple chromosomal translocations, is a novel regulator of BCR/ABL-mediated leukemogenesis.
    Perrotti D; Bonatti S; Trotta R; Martinez R; Skorski T; Salomoni P; Grassilli E; Lozzo RV; Cooper DR; Calabretta B
    EMBO J; 1998 Aug; 17(15):4442-55. PubMed ID: 9687511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of SPA-1 in phenotypes of chronic myelogenous leukemia induced by BCR-ABL-expressing hematopoietic progenitors in a mouse model.
    Kometani K; Aoki M; Kawamata S; Shinozuka Y; Era T; Taniwaki M; Hattori M; Minato N
    Cancer Res; 2006 Oct; 66(20):9967-76. PubMed ID: 17047059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Translational regulation by the p210 BCR/ABL oncoprotein.
    Perrotti D; Calabretta B
    Oncogene; 2004 Apr; 23(18):3222-9. PubMed ID: 15094772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. C/EBPdelta expression in a BCR-ABL-positive cell line induces growth arrest and myeloid differentiation.
    Gery S; Tanosaki S; Hofmann WK; Koppel A; Koeffler HP
    Oncogene; 2005 Feb; 24(9):1589-97. PubMed ID: 15674331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AML1-ETO downregulates the granulocytic differentiation factor C/EBPalpha in t(8;21) myeloid leukemia.
    Pabst T; Mueller BU; Harakawa N; Schoch C; Haferlach T; Behre G; Hiddemann W; Zhang DE; Tenen DG
    Nat Med; 2001 Apr; 7(4):444-51. PubMed ID: 11283671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.
    Barnes DJ; Palaiologou D; Panousopoulou E; Schultheis B; Yong AS; Wong A; Pattacini L; Goldman JM; Melo JV
    Cancer Res; 2005 Oct; 65(19):8912-9. PubMed ID: 16204063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Arsenic trioxide inhibits translation of mRNA of bcr-abl, resulting in attenuation of Bcr-Abl levels and apoptosis of human leukemia cells.
    Nimmanapalli R; Bali P; O'Bryan E; Fuino L; Guo F; Wu J; Houghton P; Bhalla K
    Cancer Res; 2003 Nov; 63(22):7950-8. PubMed ID: 14633726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Kinetics of proliferation, differentiation and transcription of genes regulating apoptosis in cultured human BCR/ABL+ Ph+-cells].
    Akhlynina TV; Gerasimova LP; Sarkisian GP; Borovkova TV; Dukhovenskaia EA; Manakova TE; Naĭdenova NM; Timofeev AM; Grineva NI
    Tsitologiia; 2007; 49(10):889-900. PubMed ID: 18074781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bcr-Abl has a greater intrinsic capacity than v-Abl to induce the neoplastic expansion of myeloid cells.
    Gross AW; Ren R
    Oncogene; 2000 Dec; 19(54):6286-96. PubMed ID: 11175343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation.
    Rahmani M; Nguyen TK; Dent P; Grant S
    Mol Pharmacol; 2007 Sep; 72(3):788-95. PubMed ID: 17595328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IL-2 inhibits proliferation of K562 cells and reduces accumulation of bcr/abl mRNA and oncoprotein.
    Dilloo D; Hanenberg H; Lion T; Burdach S
    Leukemia; 1995 Mar; 9(3):419-24. PubMed ID: 7885040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Restoration of C/EBPalpha expression in a BCR-ABL+ cell line induces terminal granulocytic differentiation.
    Tavor S; Park DJ; Gery S; Vuong PT; Gombart AF; Koeffler HP
    J Biol Chem; 2003 Dec; 278(52):52651-9. PubMed ID: 14517214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of novel posttranscriptional targets of the BCR/ABL oncoprotein by ribonomics: requirement of E2F3 for BCR/ABL leukemogenesis.
    Eiring AM; Neviani P; Santhanam R; Oaks JJ; Chang JS; Notari M; Willis W; Gambacorti-Passerini C; Volinia S; Marcucci G; Caligiuri MA; Leone GW; Perrotti D
    Blood; 2008 Jan; 111(2):816-28. PubMed ID: 17925491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. hnRNP A1 nucleocytoplasmic shuttling activity is required for normal myelopoiesis and BCR/ABL leukemogenesis.
    Iervolino A; Santilli G; Trotta R; Guerzoni C; Cesi V; Bergamaschi A; Gambacorti-Passerini C; Calabretta B; Perrotti D
    Mol Cell Biol; 2002 Apr; 22(7):2255-66. PubMed ID: 11884611
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Targeted blockage of RNA binding protein E2 by decoy RNA induces the granulocytic differentiation of K562 cells].
    Chen XM; Feng WL; Xu SX; Zeng JM; Zhao SQ; Luo HW; Bai WJ; Wang XZ; Huang ZG
    Zhonghua Xue Ye Xue Za Zhi; 2008 Jan; 29(1):34-8. PubMed ID: 18512313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.